COMETRIQ

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, Finland, Ireland, Lithuania, Netherlands, Poland, UK.

Active ingredients

The drug COMETRIQ contains one active pharmaceutical ingredient (API):

1	Cabozantinib UNII DR7ST46X58 - CABOZANTINIB S-MALATE
	Cabozantinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumour growth and angiogenesis, pathologic bone remodeling, drug resistance, and metastatic progression of cancer. Cabozantinib was evaluated for its inhibitory activity against a variety of kinases and was identified as an inhibitor of MET (hepatocyte growth factor receptor protein) and VEGF (vascular endothelial growth factor) receptors. In addition, cabozantinib inhibits other tyrosine kinases including the GAS6 receptor (AXL), RET, ROS1, TYRO3, MER, the stem cell factor receptor (KIT), TRKB, Fms-like tyrosine kinase-3 (FLT3), and TIE-2.
	Read more about Cabozantinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
COMETRIQ Capsule	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EX07		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EX Other protein kinase inhibitors
Discover more medicines within L01EX07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1643879, 1643880, 1643891, 1676190, 1687215, 1687226
FI	Lääkealan turvallisuus- ja kehittämiskeskus	096106, 152968, 432953
GB	Medicines & Healthcare Products Regulatory Agency	280100, 280105, 280108, 280109, 280110, 280112
LT	Valstybinė vaistų kontrolės tarnyba	1073087, 1073088, 1073089, 1077694, 1077695, 1077696
NL	Z-Index G-Standaard, PRK	118168, 201952
PL	Rejestru Produktów Leczniczych	100316734, 100316740
US	FDA, National Drug Code	42388-013